PTC Therapeutics, Inc. PTCT
63.63 USD -1.28 (-1.97%)
Nov 12, 2026, 9:44 AM EST
63.63 Day range 64.86
58.80 52-week range 90.87
- YTD
- -16.23%
- 1 year
- -15.10%
News
benzinga.com PTC Therapeutics Board Authorizes $500M Share Repurchase Program PTC Therapeutics, Inc., (NASDAQ:PTCT) today announced that its Board of Directors has authorized a share repurchase program under which PTC may repurchase up to $500 million of the Company's…
benzinga.com Citigroup Maintains Buy on PTC Therapeutics, Raises Price Target to $109 Citigroup analyst Eric Joseph maintains PTC Therapeutics (NASDAQ:PTCT) with a Buy and raises the price target from $108 to $109.- benzinga.com TD Cowen Maintains Buy on PTC Therapeutics, Raises Price Target to $95 TD Cowen analyst Joseph Thome maintains PTC Therapeutics (NASDAQ:PTCT) with a Buy and raises the price target from $90 to $95.
- benzinga.com RBC Capital Maintains Sector Perform on PTC Therapeutics, Raises Price Target to $77 RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform and raises the price target from $75 to $77.
benzinga.com Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $112 Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $109 to $112.
benzinga.com PTC Therapeutics Q3 2026 Earnings Call Transcript PTC Therapeutics (NASDAQ:PTCT) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
benzinga.com CORRECTION: PTC Therapeutics Q3 Adj. EPS $0.94 Beats $0.34 Estimate, Sales $357.807M Beat $306.399M Estimate PTC Therapeutics (NASDAQ:PTCT) reported quarterly earnings of $0.94 per share which beat the analyst consensus estimate of $0.34 by 176.47 percent. This is a 370 percent increase over earnings of…
benzinga.com PTC Therapeutics Raises FY2026 Sales Guidance from $1.180B-$1.280B to $1.290B-$1.320B vs $1.262B Est PTC Therapeutics (NASDAQ:PTCT) raises FY2026 sales outlook from $1.180 billion-$1.280 billion to $1.290 billion-$1.320 billion vs $1.262 billion estimate.- benzinga.com RBC Capital Maintains Sector Perform on PTC Therapeutics, Lowers Price Target to $75 RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform and lowers the price target from $85 to $75.
benzinga.com Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $137 Cantor Fitzgerald analyst Kristen Kluska maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $130 to $137.- benzinga.com PTC Therapeutics To Present New Sephience Data At The 2026 Society For The Study Of Inborn Errors Of Metabolism Annual Symposium, August 25-28 The presentations include new data from clinical trials and real-world evidence which reinforce the clinically meaningful benefits of Sephience on lowering phenylalanine (Phe), significant diet…
benzinga.com Barclays Maintains Overweight on PTC Therapeutics, Raises Price Target to $122 Barclays analyst Eliana Merle maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $120 to $122.
benzinga.com PTC Therapeutics Expands Rare Disease Portfolio with 'Unique Opportunity' PTC Therapeutics plans to acquire Sangamo’s ST-920 Fabry disease program for $111 million upfront, with FDA filing expected in Q4 2026.- benzinga.com Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $109 Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $106 to $109.
benzinga.com PTC Therapeutics To Acquire BLA-Stage ST-920 Fabry Disease Program; Terms Include $111M Upfront And Up To $100M In Contingent Milestone Payments Based On Certain Regulatory Approvals Planned acquisition leverages existing regulatory and commercial infrastructure and leadership's experience in Fabry therapy commercialization –– ST-920 is a one-time administered AAV gene therapy…
benzinga.com Top 3 Health Care Stocks You'll Regret Missing This Quarter The most oversold health care stocks present a buying opportunity. RSI indicator compares stock strength on up and down days, indicating short-term performance. Here's the latest list of oversold…- benzinga.com Morgan Stanley Maintains Overweight on PTC Therapeutics, Raises Price Target to $104 Morgan Stanley analyst Jeffrey Hung maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $93 to $104.
- benzinga.com Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $106 Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $93 to $106.
- benzinga.com PTC Therapeutics Raises FY2026 Sales Guidance from $1.080B-$1.180B to $1.180B-$1.280B vs $1.196B Est PTC Therapeutics (NASDAQ:PTCT) raises FY2026 sales outlook from $1.080 billion-$1.180 billion to $1.180 billion-$1.280 billion vs $1.196 billion estimate.
- benzinga.com Wells Fargo Maintains Overweight on PTC Therapeutics, Lowers Price Target to $93 Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and lowers the price target from $95 to $93.
benzinga.com Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $130 Cantor Fitzgerald analyst Kristen Kluska maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $124 to $130.- benzinga.com RBC Capital Maintains Sector Perform on PTC Therapeutics, Raises Price Target to $85 RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform and raises the price target from $82 to $85.
benzinga.com 8 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com PTC Therapeutics Announces Proposed Private Placement Of $500M Of Convertible Senior Notes Due 2031 PTC intends to grant the initial purchasers an option to purchase, within a 13-day period beginning on, and including, the date on which the Notes are first issued, up to $50.0 million of additional…- benzinga.com Jefferies Upgrades PTC Therapeutics to Buy, Raises Price Target to $85 Jefferies analyst Faisal Khurshid upgrades PTC Therapeutics (NASDAQ:PTCT) from Hold to Buy and raises the price target from $76 to $85.
- benzinga.com TD Cowen Upgrades PTC Therapeutics to Buy, Raises Price Target to $90 TD Cowen analyst Joseph Thome upgrades PTC Therapeutics (NASDAQ:PTCT) from Hold to Buy and raises the price target from $75 to $90.
- benzinga.com RBC Capital Maintains Sector Perform on PTC Therapeutics, Raises Price Target to $82 RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform and raises the price target from $81 to $82.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session - benzinga.com Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $95 Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $86 to $95.
- benzinga.com PTC Therapeutics Raises FY2026 Sales Guidance from $700.000M-$800.000M to $1.080B-$1.180B vs $1.013B Est PTC Therapeutics (NASDAQ:PTCT) raises FY2026 sales outlook from $700.000 million-$800.000 million to $1.080 billion-$1.180 billion vs $1.013 billion estimate.
- benzinga.com PTC Therapeutics Q1 EPS $(0.03) Beats $(0.48) Estimate, Sales $272.551M Beat $218.805M Estimate PTC Therapeutics (NASDAQ:PTCT) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.48) by 93.75 percent. This is a 100.3 percent decrease over earnings of…
benzinga.com PTC Therapeutics Stock Sinks As Pivotal Data Fails To Calm Sellers PTC Therapeutics stock drops after PIVOT-HD update, as FDA approval doubts offset dose-based benefits and stable safety signals.- benzinga.com PTC Therapeutics Reports Topline Results From 24-Month Interim Analysis Of PIVOT-HD Long-Term Extension Study Of Votoplam, With Favorable Dose-Dependent Effects On Disease Progression For Stage 2 HD Patients - Dose-dependent benefit on cUHDRS in Stage 2 participants compared to matched natural history cohort, with 52% slowing at 10 mg dose -- Continued evidence of favorable safety profile - - Novartis…
- benzinga.com Jefferies Downgrades PTC Therapeutics to Hold, Lowers Price Target to $76 Jefferies analyst Faisal Khurshid downgrades PTC Therapeutics (NASDAQ:PTCT) from Buy to Hold and lowers the price target from $91 to $76.
- benzinga.com Morgan Stanley Maintains Overweight on PTC Therapeutics, Raises Price Target to $92 Morgan Stanley analyst Jeffrey Hung maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $90 to $92.
- benzinga.com Wells Fargo Maintains Overweight on PTC Therapeutics, Lowers Price Target to $86 Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and lowers the price target from $93 to $86.
- benzinga.com RBC Capital Maintains Sector Perform on PTC Therapeutics, Lowers Price Target to $82 RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform and lowers the price target from $87 to $82.
- benzinga.com B of A Securities Maintains Buy on PTC Therapeutics, Lowers Price Target to $93 B of A Securities analyst Tazeen Ahmad maintains PTC Therapeutics (NASDAQ:PTCT) with a Buy and lowers the price target from $97 to $93.
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session - benzinga.com PTC Therapeutics Sees FY2026 Sales $700.000M-$800.000M vs $959.579M Est PTC Therapeutics (NASDAQ:PTCT) sees FY2026 sales of $700.000 million-$800.000 million vs $959.579 million analyst estimate.
- benzinga.com PTC Therapeutics Q4 EPS $(1.67) Misses $0.07 Estimate, Sales $164.677M Miss $276.665M Estimate PTC Therapeutics (NASDAQ:PTCT) reported quarterly losses of $(1.67) per share which missed the analyst consensus estimate of $0.07 by 2419.44 percent. This is a 96.47 percent decrease over losses of…
benzinga.com Earnings Scheduled For February 19, 2026 
benzinga.com Earnings Outlook For PTC Therapeutics 
benzinga.com PTC Therapeutics Pulls Translarna Bid After FDA Flags Weak Proof PTC Therapeutics, Inc. (PTCT) stock closed lower following the withdrawal of its New Drug Application for Translarna by the FDA.- benzinga.com PTC Therapeutics Withdraws Its New Drug Application Resubmission For Translarna For Duchenne Muscular Dystrophy Treatment After FDA Feedback PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has withdrawn the New Drug Application (NDA) resubmission for Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne…
benzinga.com What's Going On With Royalty Pharma Stock Wednesday? Royalty Pharma has acquired PTC's remaining royalty on Roche's Evrysdi for $240 million upfront and sales-based milestones.
benzinga.com Amazon To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Monday 
benzinga.com Earnings Scheduled For November 4, 2025 - benzinga.com Earnings Scheduled For August 7, 2025
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session